House Bill Would Credit Some Cash Drug Purchases to Deductibles

A House bill would require group and individual health plans to count some prescription drugs bought outside the insurance benefit toward a patient's deductible and out-of-pocket maximum. The proposal addresses a real accounting gap, but it is not a general rule for every cash purchase and it has not become law.

Representative Gregory Murphy of North Carolina introduced H.R. 8270, the Every Dollar Counts Act of 2026, on April 14 with four Republican cosponsors. The official record lists referral to the House Energy and Commerce, Education and Workforce, and Ways and Means committees. It lists no later legislative action.

The Idea Emerged From the White House Drug-Pricing Push

STAT reported in March that White House officials had shared draft drug-pricing legislation with pharmaceutical companies. According to that report, the draft included a policy allowing cash drug purchases to count toward a patient's deductible. The administration later described deductible and out-of-pocket credit as part of proposed legislation accompanying its most-favored-nation pricing framework and TrumpRx direct-purchase program.

H.R. 8270 is the public legislative text that now permits a precise reading. It is much shorter than the surrounding political debate. The bill changes how qualifying patient spending would be credited; it does not itself set a prescription price, establish an international price benchmark or guarantee that a cash offer is the cheapest available option.

The Drug Must Already Be Eligible for Plan Benefits

The bill applies when an enrolled person buys a drug "for which benefits are available" under the health plan but elects to purchase it without applying those benefits. The plan would then count the person's out-of-pocket expenditure toward the deductible and out-of-pocket maximum that would have applied if the benefit had been used.

That wording matters. The proposal does not say that every noncovered medicine or every product sold for cash must count. It ties the credit to a drug for which the plan offers benefits. Questions about formulary status, prior authorization or other coverage conditions would therefore need clear implementation guidance.

The Credit Would Reach Beyond the Deductible

Public discussion often shortens the proposal to cash spending counting toward a deductible. The introduced text also covers the plan's out-of-pocket maximum. Those are different thresholds: a deductible generally governs when a plan begins sharing certain costs, while the annual maximum limits the covered cost sharing an enrollee must pay under the plan's rules.

The bill says the cash expenditure should count toward the thresholds that would have applied had the patient used the benefit. It does not say the health plan must reimburse the cash purchase. A patient could receive accounting credit without receiving money back for the transaction itself.

The Bill Covers Private Plan Statutes

H.R. 8270 would add parallel requirements to the Public Health Service Act, the Employee Retirement Income Security Act and the Internal Revenue Code. That structure reaches group health plans and insurers offering group or individual coverage through the statutes that govern private health benefits.

Separate conforming provisions would exclude certain direct-purchase price reductions from Medicaid best-price and average-manufacturer-price calculations. Those exclusions concern how manufacturer pricing is calculated; they do not convert the bill into a universal prescription benefit or prove that its direct-purchase provisions will lower total drug spending.

January 2027 Is Conditional, Not a Start Date

The introduced bill says its main counting amendments would apply to plan years beginning on or after January 1, 2027. That date matters only if Congress passes the measure and it is signed into law. An effective-date clause inside an introduced bill is not evidence that health plans must already change their systems.

As of the latest official action listed by GovInfo, the measure remains at the introduced-and-referred stage. It has not passed the House, passed the Senate or reached the president. Patients should therefore continue to check their current plan rules rather than assume an outside cash purchase will receive credit.

The Operational Rules Are Still Missing

The statutory language creates a duty to count qualifying spending but does not specify the transaction system. Regulators and plans would need a reliable way to verify the patient, prescription, drug, amount paid and date of purchase, then post the correct credit without requiring burdensome manual claims.

Other questions include how quickly a credit must appear, how a patient challenges a missing entry, how duplicate claims are prevented and what documentation a direct seller or pharmacy must provide. Those details will decide whether the policy works at the counter or becomes a delayed paperwork exercise.

Deductible Credit Is Not the Same as a Lower Price

The proposal could remove a penalty faced by some insured patients: choosing a lower cash price may save money on one fill while making no progress toward the plan's annual thresholds. Crediting the payment could allow the immediate saving and the insurance accounting to coexist.

But the bill does not demonstrate how many patients would benefit, how much they would save or how plans would respond. It does not lower list prices by itself. Its direct effect is to change which patient-paid dollars count, not to prove a reduction in premiums, total spending or the price of every prescription.

The Test Is a Verifiable Credit, Not a Political Label

The cleanest case for H.R. 8270 is fairness: if a covered drug costs less outside the benefit, a patient should not necessarily lose progress toward the same plan thresholds by choosing the lower price. The cleanest caution is equally specific: legislation must define eligibility and verification well enough that the credit appears accurately and promptly.

For now, the proposal is neither a completed Trump drug-pricing reform nor a guaranteed patient saving. It is an introduced bill with a narrow accounting rule and unresolved implementation work. Its value will be measured by whether qualifying patients can document a cheaper purchase and see the correct deductible and out-of-pocket credit, not by how broadly politicians describe the drug-pricing agenda around it.